Language:

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

The New England journal of medicine, 2020-09, Vol.383 (10), p.931-943 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2004407 ;PMID: 32469185

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Author: Paik, Paul K ; Felip, Enriqueta ; Veillon, Remi ; Sakai, Hiroshi ; Cortot, Alexis B ; Garassino, Marina C ; Mazieres, Julien ; Viteri, Santiago ; Senellart, Helene ; Van Meerbeeck, Jan ; Raskin, Jo ; Reinmuth, Niels ; Conte, Pierfranco ; Kowalski, Dariusz ; Cho, Byoung Chul ; Patel, Jyoti D ; Horn, Leora ; Griesinger, Frank ; Han, Ji-Youn ; Kim, Young-Chul ; Chang, Gee-Chen ; Tsai, Chen-Liang ; Yang, James C.-H ; Chen, Yuh-Min ; Smit, Egbert F ; van der Wekken, Anthonie J ; Kato, Terufumi ; Juraeva, Dilafruz ; Stroh, Christopher ; Bruns, Rolf ; Straub, Josef ; Johne, Andreas ; Scheele, Jürgen ; Heymach, John V ; Le, Xiuning
Subjects: Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Binding sites ; Biopsy ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Edema ; Edema - chemically induced ; Enrollments ; Exons ; Female ; Humans ; Lung cancer ; Lung cancer, Non-small cell ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Male ; Metastases ; Metastasis ; Middle Aged ; Mutation ; Non-small cell lung carcinoma ; Patient outcomes ; Piperidines - adverse effects ; Piperidines - therapeutic use ; Population ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Proto-Oncogene Proteins c-met - antagonists & inhibitors ; Proto-Oncogene Proteins c-met - genetics ; Pyridazines - adverse effects ; Pyridazines - therapeutic use ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Quality of life ; Questionnaires ; Small cell lung carcinoma ; Transcription ; Tumors
Is Part Of: The New England journal of medicine, 2020-09, Vol.383 (10), p.931-943
Description: In a study involving patients with non–small-cell lung cancer with a MET exon 14 skipping mutation, the use of tepotinib (a selective MET inhibitor) was associated with a partial response in approximately half the patients. The main adverse event was peripheral edema.
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa2004407
PMID: 32469185
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2004407 ;PMID: 32469185

Searching Remote Databases, Please Wait